The Effect of Antipsychotic-Induced Weight Gain in Individuals with Severe Mental Illness: Understanding the Impact and Looking at a Novel Pharmacological Intervention
Year: 2025
Type: dissertation
Abstract: Antipsychotic-induced weight gain or AIWG is a growing cause for concern among individuals with severe mental illnesses (SMIs). However, our current understanding of the impact of AIWG on the psychiatric population alongside the potential impact of a new treatment that shows promise in the general population is limited. This thesis sought to address these gaps in the literature via three studies in the SMI population. In Study 1, the objective was to compare whether weight gain as a known side-effect of antipsychotic use, may cause nonadherence or discontinuation of these medications through a systematic review and meta-analysis. In Study 2, a new pharmacological intervention called semaglutide, which is now approved for use in overweight and obese individuals, was assessed among inpatients with SMI at the Centre for Addiction and Mental Health via a retrospective chart review. This study examined the impact of semaglutide treatment on weight change over 12 months among these inpatients, alongside associated metabolic variables such as BMI, HbA1c levels, and lipid parameters. In Study 3, the same medication was compared against placebo in a 32-week single-blind randomized controlled trial (RCT) to evaluate how weight and other metabolic variables such as glucose parameters and lipid levels may change over time. Collectively, these studies provided strong evidence regarding the detrimental effect of AIWG on the lives of patients and the importance of addressing this condition in a vulnerable population. Study 1 showed that AIWG does in fact lead to greater nonadherence among patients, and that antipsychotics with a higher propensity for weight gain result in increased nonadherence or discontinuation compared to those with lower propensity for weight gain. This is a finding that is particularly concerning as it can lead to disease exacerbation and a decline in an individual’s quality of life. Studies 2 and 3 then offered promising new evidence in support of semaglutide, which shows strong potential as an effective weight mitigation strategy within the SMI population.
Source: TSpace (University of Toronto)
Author: De, Riddhita
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7133006491
